X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Novartis with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs GLENMARK PHARMA - Comparison Results

NOVARTIS    Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS GLENMARK PHARMA NOVARTIS/
GLENMARK PHARMA
 
P/E (TTM) x 273.1 18.8 1,455.5% View Chart
P/BV x 29.2 3.4 868.8% View Chart
Dividend Yield % 1.6 0.4 435.8%  

Financials

 NOVARTIS   GLENMARK PHARMA
EQUITY SHARE DATA
    NOVARTIS
Mar-18
GLENMARK PHARMA
Mar-17
NOVARTIS/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs758993 76.3%   
Low Rs579729 79.4%   
Sales per share (Unadj.) Rs228.4325.5 70.2%  
Earnings per share (Unadj.) Rs31.739.3 80.8%  
Cash flow per share (Unadj.) Rs32.848.7 67.3%  
Dividends per share (Unadj.) Rs10.002.00 500.0%  
Dividend yield (eoy) %1.50.2 644.1%  
Book value per share (Unadj.) Rs297.1159.2 186.6%  
Shares outstanding (eoy) m24.69282.17 8.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.92.6 110.7%   
Avg P/E ratio x21.121.9 96.1%  
P/CF ratio (eoy) x20.417.7 115.3%  
Price / Book Value ratio x2.25.4 41.6%  
Dividend payout %31.55.1 619.0%   
Avg Mkt Cap Rs m16,505242,991 6.8%   
No. of employees `0000.713.0 5.2%   
Total wages/salary Rs m1,44516,408 8.8%   
Avg. sales/employee Rs Th8,441.37,083.9 119.2%   
Avg. wages/employee Rs Th2,163.61,265.4 171.0%   
Avg. net profit/employee Rs Th1,173.1855.1 137.2%   
INCOME DATA
Net Sales Rs m5,63991,857 6.1%  
Other income Rs m1,718374 459.9%   
Total revenues Rs m7,35792,230 8.0%   
Gross profit Rs m-6320,367 -0.3%  
Depreciation Rs m252,644 1.0%   
Interest Rs m552,373 2.3%   
Profit before tax Rs m1,57515,724 10.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-810 0.0%   
Tax Rs m7923,827 20.7%   
Profit after tax Rs m78411,088 7.1%  
Gross profit margin %-1.122.2 -5.0%  
Effective tax rate %50.324.3 206.5%   
Net profit margin %13.912.1 115.1%  
BALANCE SHEET DATA
Current assets Rs m9,52268,746 13.9%   
Current liabilities Rs m3,29627,027 12.2%   
Net working cap to sales %110.445.4 243.1%  
Current ratio x2.92.5 113.6%  
Inventory Days Days3785 43.1%  
Debtors Days Days2896 29.8%  
Net fixed assets Rs m4624,132 0.2%   
Share capital Rs m123282 43.7%   
"Free" reserves Rs m7,21344,643 16.2%   
Net worth Rs m7,33644,925 16.3%   
Long term debt Rs m045,363 0.0%   
Total assets Rs m11,105117,639 9.4%  
Interest coverage x29.57.6 386.7%   
Debt to equity ratio x01.0 0.0%  
Sales to assets ratio x0.50.8 65.0%   
Return on assets %7.611.4 66.0%  
Return on equity %10.724.7 43.3%  
Return on capital %22.219.1 116.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6156,152 0.1%   
Fx outflow Rs m3,6308,084 44.9%   
Net fx Rs m-3,57048,068 -7.4%   
CASH FLOW
From Operations Rs m1,6106,574 24.5%  
From Investments Rs m687-7,124 -9.6%  
From Financial Activity Rs m-2,6775,432 -49.3%  
Net Cashflow Rs m-3801,992 -19.1%  

Share Holding

Indian Promoters % 0.0 48.3 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 2.0 6.9 29.0%  
FIIs % 1.6 34.4 4.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.5 10.5 204.8%  
Shareholders   41,647 56,727 73.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   PIRAMAL ENTERPRISES  ABBOTT INDIA  PANACEA BIOTECH  DR. REDDYS LAB  GSK PHARMA  

Compare NOVARTIS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex at All-Time High; Energy & IT Stocks Top Gainers(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 1% while the Hang Seng is up 0.3%.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6%

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

Glenmark: Zetia Bolsters Sales and Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

The 180-day exclusivity for Zetia enabled Glenmark to show strong growth in sales and profits during the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

How to Avoid a 90% Loss Suffered by This Super Investor(The 5 Minute Wrapup)

Jul 12, 2018

Blindly following super investors is a dangerous game to play. Here's how you can avoid such mistakes.

The Answer to Your Wealth Worries: Small Caps (Especially Now)(Profit Hunter)

Jul 10, 2018

If you're worried about the markets - you are on the wrong track. This is opportunity - put your wealth-building hat on, instead - Richa shows you how...

The Multiple Problems with the Minimum Support Price (MSP) System(Vivek Kaul's Diary)

Jul 11, 2018

The price signals that MSP sends out, creates its own set of problems.

New Fund Offer - ICICI Prudential Pharma Healthcare and Diagnostics Fund - Should You Invest?(Outside View)

Jul 6, 2018

ICICI AMC launches an open -ended equity fund following Pharma, Healthcare, Diagnostic and allied theme.

When Disappointment Panda is Around. Buy Quality Stock like This!(Chart Of The Day)

Jul 6, 2018

Buy Companies that can fight all kinds of Pandas and Bears in the long run.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Jul 18, 2018 10:23 AM

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - PANACEA BIOTECH COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS